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Abstract: Chemotherapy-induced nausea and vomiting (CINV) remain the most common and
devastating side-effects associated with cancer chemotherapy. In recent decades, several lines of
research emphasize the importance of 5-hydroxytryptamine3 (5-HT3; serotonin) receptors in the
pathogenesis and treatment of CINV. 5-HT3 receptors are members of ligand-gated ion channels that
mediate the rapid and transient membrane-depolarizing effect of 5-HT in the central and peripheral
nervous system. These receptors play important roles in nausea and vomiting, as well as regulation
of peristalsis and pain transmission. The development of antagonists for 5-HT3 receptor dramatically
improved the treatment of CINV in cancer patients. In fact, the most common use of 5-HT3 receptor
antagonists to date is the treatment of nausea and vomiting. In recent years, there has been an
increasing tendency to use natural plant products as important therapeutic entities in the treatment
of various diseases. In this article, we examined the results of earlier studies on the actions of natural
compounds on the functional properties of 5-HT3 receptors. It is likely that these natural modulators
of 5-HT3 receptors can be employed as lead structures for the synthesis of therapeutic agents for
treating CINV in future clinical studies.
Keywords: chemotherapy-induced nausea and vomiting; 5-hydroxytryptamine3 receptors;
5-hydroxytryptamine3 receptor antagonists; negative allosteric modulators

1. Introduction
Chemotherapy-induced nausea and vomiting (CINV) remain the most common and devastating
side-effects associated with cancer treatment. These side effects can lead to the development of serious
clinical complications such as electrolyte imbalance, dehydration, weight loss, weakness, fractures
and deterioration in behavioral and mental status of the patient. In addition, these side effects can
interfere with compliance with treatment as patients may delay or refuse future treatments because
of fear of further nausea and vomiting [1,2]. Recently, a number of approaches have been applied to
control CINV including medicinal or complementary therapies and the selection and prescription of
appropriate approaches will significantly improve the patients’ quality of life.
Chemotherapy treatments received in cancer patients are classified into high emetic risk (emesis in
nearly all patients), moderate emetic risk (30–90% risk of emesis), low emetic risk and minimal emetic
risk emetogenic chemotherapies [3–5]. Compared to cisplatin, melphalan, cyclophosphamide and
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dacarbazine, which have high emetogenic potential, other chemotherapy agents such as anthracyclines,
methotrexate, oxaliplatin and carboplatin have moderate emetogenic properties [3–5]. Depending
on the chemotherapeutic agents and frequency of administration, patients can develop both acute
and delayed CINV. According to the most recent guidelines from major medical organizations
such as National Comprehensive Cancer Network and American Society of Clinical Oncology,
the use of 5-hydroxytryptamine3 (5-HT3 ; serotonin) receptor antagonist, in combination with and
neurokinin1 receptor antagonist (aprepitant) and the corticosteroid dexamethasone is recommended
in patients receiving moderately emetogenic chemotherapy [4,5]. In the case of highly emetogenic
therapy, a four-drug regimen is recommended, including 5-HT3 receptor antagonist, neurokinin1
receptor antagonist, dexamethasone and the antipsychotic drug olanzapine [4,5]. To date, the most
commonly used 5-HT3 receptor antagonists are granisetron and ondansetron (first-generation 5-HT3
receptor antagonists) and palonosetron (second-generation 5-HT3 receptor antagonists) [3,5]. While
granisetron and ondansetron have significant efficacy in the prevention of acute CINV (0–24 h
after chemotherapy) in cancer patients receiving moderately and highly emetogenic chemotherapy,
palonosetron has a higher potency and efficacy for the management of delayed CINV (after 24–120 h
after chemotherapy) [3,6,7]. When combined with 5-HT3 receptor antagonist and dexamethasone, the
neurokinin1 receptor antagonist aprepitant prevents CINV in patients receiving highly emetogenic
chemotherapy [8]. This four-drug regimen is recommended for the control of both acute and delayed
CINV [3,9].
The concept that 5-HT3 and its receptors are involved in the emetic reflex was revealed in
several earlier studies [10,11]. In addition to the classic 5-HT3 receptor antagonists, there are many
natural compounds derived from plants which inhibit 5-HT3 receptors such as the alkaloids cocaine
and morphine (for review, [12]), the antimalarial drug quinine [13], cannabinoids, nicotine and
terpenes [12,14,15]. In fact, there has been an increasing tendency towards using natural plant
products as important therapeutic entities in the treatment of different illnesses. As such, these
agents have advantages over synthetic drugs because they have fewer side effects (such as headache
and constipation) in patients undergoing CINV [16] and are more cost-effective [17].
Allosteric modulators alter the receptor conformation by binding to a site distinct from the
endogenous agonist binding site (orthosteric site) [18]. As a result, the binding and/or functional
properties of agonist binding to orthosteric site may be affected [19]. Negative allosteric modulators
decrease the efficacy of the endogenous receptor agonist without inducing complete receptor inhibition
caused by orthosteric inhibitors and therefore, maintain the native pattern of the receptor activation
largely intact [18,20,21]. Compared to homomeric receptors, the heteromeric 5-HT3 receptor contains
an increased number of potential allosteric sites for drug interaction. As allosteric sites exhibit
greater structural diversity than orthosteric sites, they are more likely to allow selective targeting by
modulators than orthosteric sites [18,20,21]. In this article, we examine the results of earlier studies on
the actions of natural negative allosteric modulators of 5-HT3 receptors. Natural negative allosteric
modulators of 5-HT3 receptors could be used as useful therapeutic agents in the treatment of CINV in
the future.
2. 5-hydroxytryptamine3 Receptors
5-HT3 receptors represent one of the seven families of serotonin receptors (5-HT1–7 ). They are
members of the Cys-loop ligand-gated ion channel family and therefore, they differ structurally and
functionally from the other six classes of G-protein coupled serotonin receptors [22]. The functional
5-HT3 receptor is a pentamere of five subunits that surround a water-filled ion channel [23,24].
Each subunit is made of 3 domains: (1) An extracellular domain that forms the ligand-binding site,
(2) A transmembrane domain consisting of four membrane-spanning helices (M1–M4) that facilitate
ion movement across the membrane, and (3) An intracellular domain formed by the large M3–M4
intracellular loop, which is responsible for receptor modulation, sorting, and trafficking, and contains
openings that impact ion conductance [23–25]. The endogenous ligand binding site is located in the
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extracellular domain at the interface of two adjacent subunits, where binding is coordinated by the
convergence of six peptide loops [26]. To date, the five different subunits (A–E) of 5-HT3 receptor have
been cloned but only the A and B subunits have been studied extensively. Moreover, all functional
5-HT3 receptors require the presence of at least one A subunit [25].
5-HT3 receptors are located in many brain areas and are believed to play important roles in
psychiatric disorders such as depression, motility of gastrointestinal system, emesis, neurodevelopment
and nociception, [12,25,27]. Like other channels that are permeable to the cations, Na+ , K+ , and
Ca2+ [28–30], the 5-HT3 receptors mediate fast excitatory depolarizing responses in pre- and post-synaptic
neurons in the central and peripheral nervous system [31].
3. 5-hydroxytryptamine3 Receptor-Mediated Nausea and Vomiting
The role of 5-HT3 receptors in nausea and vomiting has been well-established [32,33].
The mechanism by which nausea and vomiting are triggered involves 5-HT3 receptors both in the
central nervous system and the gastrointestinal tract [34]. Vomiting is triggered when afferent impulses
from the cerebral cortex, chemoreceptor trigger zone and vagal afferent fibers of the gastrointestinal
tract travel to the vomiting center, located in the medulla. Efferent impulses then travel from the
vomiting centre to the abdominal muscles, cranial nerves, salivation centre, and respiratory centre,
causing vomiting [35]. Large numbers of 5-HT3 receptors are expressed by enteric sensory neurons in
the mucosal layer and in the nerve cell body of interneurons and motor neurons in the enteric nervous
system [36]. It has been suggested that vomiting occurs because of the stimulation of enterochromaffin
cells of the intestinal mucosa which results in the release of 5-HT and subsequent stimulation of
peripheral 5-HT3 receptors of ganglionic and synaptic transmission in the myenteric plexus. This action,
along with the local release of 5-HT in the area postrema, located on the dorsal surface of the medulla
oblongata, is suggested to trigger the vomiting reflex [37].
Currently, there is a wide range of 5-HT3 antagonists available for clinical use. In fact, drugs that
selectively antagonize 5-HT3 receptors are currently among the most effective antiemetic agents, and
therefore are considered the “gold standard” in the treatment of CINV [25,34,37]. However, the wide
use of synthetic antiemetic drugs has been accompanied with adverse side effects such as headache,
hypotension and extra pyramidal side effects [17]. Furthermore, they are ineffective in up to 30%
of CINV cases [16,38], warranting the search for more effective anti-emetics for CINV treatment. In
this aspect, plants have drawn significant interest in the field of treatment of CINV as compared to
chemical drugs due to having more advantages, fewer side effects in patients undergoing CINV, as
well as being more cost-effective [17].
4. Natural Negative Allosteric Modulators of 5-hydroxytryptamine3 Receptors
As 5-HT3 receptor antagonists were found to be effective antiemetic agents against CINV, much
interest was drawn towards identifying agents that are capable of affecting/modulating the function
of 5-HT3 receptors [11,39]. In the below sections, we review the effects of natural negative allosteric
modulators of 5-HT3 receptors.
4.1. Terpenes
Menthol is a monocyclic terpene alcohol (Figure 1) and a natural product of the peppermint plant
Mentha × piperita (Lamiaceae). It is commonly used as part of analgesic, antiseptic, topical antipruritic,
and cooling formulations. In addition, it is widely used as a natural product in cosmetics, a flavoring
agent, and as an intermediate in the production of other compounds. Menthol-containing medications
are currently available for a number of conditions, including respiratory diseases, gastrointestinal
disorders, common cold, and musculoskeletal pain [40–42].
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1: Natural
negative
allosteric
modulators
of 5-HT
receptor.
Figure
1. Natural
negative
allosteric
modulators
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3 receptor.

Several studies have reported the potential modulatory effect of menthol on the 5-HT3
receptor [15,43–45] (Table 1). An earlier study conducted by Heimes et al., 2011 used three
in vitro models to investigate the effects of peppermint oil and its active constituent, menthol, on
5-HT3 receptors. The models included [14 C] guanidinium influx into N1E-115 cells which express
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5-HT3 receptors, isotonic contractions of ileum isolated rat and equilibrium competition binding
studies using GR65630 (3-(5-methyl-1H-imidazol-4-yl)-1-(1-methyl-1H-indol-3-yl)-1-propanone, a
radioactively-labeled 5-HT3 receptor antagonist. Both peppermint oil and menthol, inhibited
the serotonin-induced flux of [14 C] guanidinium into N1E-115 cells that express 5-HT3 receptors
in a concentration-dependent manner. Furthermore, both compounds were able to reduce
serotonin-induced contraction of the ileum isolated from rat. Interestingly, peppermint oil and menthol
did not compete for the binding site on 5-HT3 receptor, which suggests that they bind to an allosteric
binding site that is distinct from the binding site of serotonin [44].
The effects of menthol on the functional properties of human 5-HT3A receptors expressed in Xenopus
laevis oocytes have been studied by Ashoor et al. [43]. Menthol, at an IC50 value of 163 µM, caused an
inhibition of the 5-HT-induced inward current. The menthol effect was concentration-dependent and was
G-protein-independent as GTPγS activity was unchanged. Furthermore, pretreatment with Gi and Go
inhibitor, pertussis toxin, did not alter the inhibitory effect of menthol. Furthermore, menthol actions were
not stereo-selective as (+), (−) and racemic menthol inhibited the currents mediated by 5-HT3 receptor
in the same manner [43]. Supporting the data observed by Heimes et al. [44], menthol did not affect
the binding of the orthosteric 5-HT3 receptor antagonist, GR65630 the 5-HT binding site. In addition,
increasing the concentration of 5-HT did not alter the inhibitory effect of menthol, which indicates that
menthol acts as an allosteric modulator of 5-HT3 receptor as a non-competitive antagonist. Interestingly,
menthol has also been shown as a negative allosteric inhibitor of α7 [46] and α4 β2 [47,48] nicotinic
acetylcholine receptors. Apart from its effect on 5-HT3 and nicotinic acetylcholine receptors, menthol was
also found to activate TRPM8 receptors [49,50] and receptors for inhibitory neurotransmitters, including
GABAA and Glycine [51–54] (Table 2).
Table 1. Summary of natural negative allosteric inhibitors of 5HT3 receptor.
Compound

Concentration
>100 µM

Menthol

IC50 = 163 µM
IC50 = 4.75 µM
IC50 = 489 µM

Preparation
[14 C] guanidinium influx into N1E-115 cells.
Isotonic contractions of the ileum isolated rat.
Equilibrium competition binding studies.
Xenopus laevis oocytes
HEK293 cells
Xenopus laevis oocytes

References
[44]
[43]
[15]
[45]

Boldine

IC50 = 5.94 µM

HEK293 cells

[15]

Citronellol

IC50 = 64.3 µM

Xenopus laevis oocytes

[45]

Geraniol

IC50 = 188 µM

Xenopus laevis oocytes

[45]

Citral

IC50 = 120 µM

Xenopus laevis oocytes and HEK293 cells

[55]

Eucalyptol

IC50 = 258 µM

Xenopus laevis oocytes and HEK293 cells

[55]

Linalool

IC50 = 141 µM

Xenopus laevis oocytes and HEK293 cells

[55]

6-shogaol

100 µM
IC50 = 3.2–10 µM

[14 C] guanidinium influx into N1E-115 cells.
Equilibrium competition binding studies.
Isotonic contractions of the isolated guinea-pig ileum.
Visceral afferent neurons and HEK293 cells.

8-gingerol

1–3 µM
100 µM

[14 C] guanidinium influx into N1E-115 cells.
Equilibrium competition binding studies.
Isotonic contractions of the isolated guinea-pig ileum.

[56]

6-gingerol

88 µM
100 µM
IC50 = 9–30 µM

[14 C] guanidinium influx into N1E-115 cells.
Equilibrium competition binding studies.
Isotonic contractions of the isolated guinea-pig ileum.
Visceral afferent neurons and HEK293 cells

[56–58]

10-gingerol

IC50 = 9–15 µM

[14 C] guanidinium influx into N1E-115 cells.
Equilibrium competition binding studies.
Isotonic contractions of the isolated guinea-pig ileum.

[56]

Zingerone

IC50 = 1.19 mM

Visceral afferent neurons

[58]

Capsaicin

IC50 = 98.1 µM

Xenopus laevis oocytes

[45]

Eugenol

IC50 = 1159 µM

Xenopus laevis oocytes

[45]

Vanillin

IC50 = 4744 µM

Xenopus laevis oocytes

[45]

Thujone

-

Cannabidiol
Quinine

[56,57]

HEK293 cells

[59]

IC50 = 0.6 µM

Xenopus laevis oocytes

[60]

IC50 = 1.06 µM

Xenopus laevis oocytes

[13]

Molecules 2018, 23, 3186

6 of 15

Table 2. Summary of the effects of natural negative allosteric inhibitors of 5HT3 on other target proteins.
Compound

Target protein

Effect

References

GABAA
Glycine

Potentiation
Potentiation
Reduction
Up-regulation
Potentiation
Blocking
Inhibition
Activation
Activation
Inhibition

[52–54]
[51]
[47,61,62]
[63]
[49,50]
[64]
[65–67]
[68]
[49,50,69]
[70]

Nicotinic receptors
Menthol

TRP channels
Na+ channels
Ca2+ channels
K+ channels
TRP channels

Boldine

TRP channels

Inhibition

[71]

Citral

TRP channels

Activation

[72]

Na+

Eucalyptol

channels
TRP channels

Inhibition
Activation

[73]
[74–76]

Linalool

Na+ channels
Nicotinic receptors
TRP channels

Inhibition
Reduction
Activation

[77]
[78]
[74,79]

Gingerol

L-type Ca2+ channels

Inhibition

[80]

Blockage
Inhibition

[81]
[82]

6-gingerol

Na+

channels
K+ channels

6-shogaol

Na+ channels

Blockage

[81]

Capsaicin

K+ channels

Inhibition

[82]

Eugenol

T-type Ca2+ channel
GABAA receptors
K+ channels

Inhibition
Activation
Inhibition

[83,84]
[85,86]
[87,88]

Cannabidiol

TRP channels
α7 -nicotinic receptors
Glycine receptors

Activation
Inhibition
Activation

[74,89,90]
[91]
[92]

Thujone

TRP channels
α7 -nicotinic receptors
GABAA receptors

Activation
Inhibition
Inhibition

[93]
[94]
[95]

Walstab et al. investigated the actions of the aporphine alkaloid boldine and menthol isomers
on human recombinant homomeric 5-HT3A and heteromeric 5-HT3AB receptors expressed in HEK293
cells utilizing luminescence-based Ca2+ assay, membrane potential assay and radioligand binding
assay. Both compounds inhibited the 5-HT-induced activation of 5-HT3 receptors at micromolar
concentrations. Boldine was a more potent inhibitor to 5-HT3A compared to 5-HT3AB receptors.
Interestingly, menthol inhibited both receptors in a non-competitive and stereo-selective manner.
(+)-menthol had less potent inhibitory action compared to the (−)-menthol which was 11-fold potent
towards the homomeric 5-HT3A receptor [15].
In a recent study, the actions of a number of terpenes and pungent substances on human 5-HT3A
receptors recombinantly expressed in Xenopus laevis oocyte were tested [45]. The results of this study
have shown that 5-HT3A receptors are inhibited by a variety of terpenes and pungent substances with
some of them belonging to the vanilloid class. Within the acyclic monoterpenes tested, citronellol and
geraniol, which are known as the main constituents of Rosa damascena flower essential oils [96], were
the most potent blockers for 5-HT3A receptors. Citronellol decreased the 5-HT3A receptor-mediated
currents with an IC50 of 64 µM. Geraniol was less potent compared to citronellol with an IC50 of
188 µM. (−)-Menthol also decreased the 5-HT3A receptor-mediated currents but with lower potency
than citronellol (IC50 489 µM) [45]. As citronellol and geraniol have structures similar to menthol,
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further studies are warranted to test if these compounds utilize the same binding site as menthol on
the 5-HT3A receptors.
The effects of terpenoids on 5-HT3 receptors were also recently studied by Jarvis et al. [97].
The terpenoids citral, eucalyptol, and linalool were tested for their effects on the electrophysiological
and binding properties of human 5-HT3 receptors expressed in Xenopus oocytes and HEK293 cells,
respectively [97]. All of the terpenoids inhibited 5-HT3 receptors with IC50 values in the µM range
(citral IC50 = 120 µM; eucalyptol IC50 = 258 µM; linalool IC50 = 141 µM) [97]. The IC50 values were also
comparable to those for similar terpenoid compounds, such as menthol (163 µM) [43].
In addition, all the tested compounds non-competitively inhibited the maximal 5-HT in a
concentration-dependent manner and did not compete with the fluorescently-labelled antagonist
granisetron. Homology modeling and ligand docking predicted the binding to a transmembrane
cavity at the interface of adjacent subunits. This can be explained by the lipophilic nature of these
compounds. In fact, the results are consistent with the slow wash-in and wash-out that is observed as
the compounds diffuse into the membranes before reaching their target [55]. Collectively, the effects of
terpenoids on 5-HT3 receptors can be added to the increasing list of structurally related natural plant
compounds that modulate voltage- and ligand-gated ion channels [15,45,46,51,98–101].
4.2. Ginger Constituents
The rhizome of Zingiber officinale Roscoe (Zingiberaceae), commonly known as ginger, has been
used for centuries in treating pregnancy-induced nausea and vomiting [102,103]. The anti-emetic
effect of ginger and its active constituents have been investigated in earlier studies to establish the
mechanism for their antiemetic activity [12,104,105]. The best characterized constituents of ginger
are the pungent substances gingerols and shogaols [56,106]. In particular, the compounds 6-, 8-,
10-gingerol and 6-shogaol were shown in different in vivo studies to be, at least, partly responsible
for the anti-emetic properties of ginger [107,108]. In this regard, Abdel-aziz et al. [106] used three
different in vitro models to investigate the effects of ginger extracts on 5-HT3 receptors: 1) [14 C]
guanidinium influx into N1E-115 cells which express 5-HT3 receptors, 2) isotonic contractions
of the isolated guinea-pig ileum induced by the highly selective HT3 receptor agonist SR57227A
((4-amino)-(6-chloro-2-pyridyl)L-piperidine hydrochloride), and 3) equilibrium competition binding
studies using a radioactively labeled 5-HT3 receptor antagonist ([3 H]GR65630). All tested ginger
extracts caused concentration-dependent inhibition of [14 C] guanidinium influx through 5-HT3 receptor
channels as well as contractions of the guinea-pig ileum induced by SR57227A. The order of potency for
both models was: 6-shogaol ≥ 8-gingerol 10-gingerol ≥ 6-gingerol. These compounds did not displace
the 5-HT3 antagonist [3 H]GR65630 from the ligand binding site neither on intact N1E-115 cells nor on
the purified membranes of HEK-293 cells over-expressing the h5-HT3 receptor indicating that they
are non-competitive inhibitors of 5-HT3 receptors [106]. Similarly, in the guinea pig myenteric plexus
preparation (bioassay for contractile 5-HT3 receptors), the 5-HT maximal responses were depressed
by 10-gingerol and 6-shagoal. 10-gingerol decreased the response to 5-HT from 93% to 65% at an
antagonist concentration of 3 µM and to 48% at an antagonist concentration of 5 µM. 6-Shogaol (3 µM)
was less potent compared to 10-gingerol and induced depression to 61% at an antagonist concentration
of 3 µM. It is concluded that the efficacy of ginger in reducing nausea and vomiting may be based on
the inhibitory effect of gingerols and shogaols at 5-HT3 receptors [56].
In support of the above study, Walstab et al. [109] showed that ginger extracts and its pungent
constituents inhibited the activation of human 5-HT3A and 5-HT3AB receptors heterologously
expressed in HEK293 cells in a concentration-dependent manner [109]. Furthermore, with increasing
concentration of pungent compounds, ginger extracts inhibited both receptors, confirming that they
are part of ginger’s active principle. Inhibition potencies of 6-gingerol and 6-shogaol on both receptors
were in the low µM range. The non-competitive inhibition of 5-HT3A and 5-HT3AB receptors by ginger
extract was confirmed by [3 H]GR65630 binding, showing that the ginger extract did not displace the
radioligand from 5-HT3A and 5-HT3AB receptors.
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In addition to the previously mentioned ginger extracts, Jin et al. reported that zingerone is a
non-competitive inhibitor of 5-HT3 on visceral afferent neurons [58]. Using patch-clamp methods,
they showed that zingerone inhibited the 5-HT response in a manner similar to the pungent
substances 6-shogaol and 6-gingerol. The order of inhibitory potency for these compounds were
6-shogaol >6-gingerol >zingerone. The IC50 of 6-shogaol and 6-gingerol were 128 and 39 times
lower than zingerone, respectively, indicating that 6-shogaol and 6-gingerol are more effective than
zingerone. Unlike the competitive 5-HT3 receptor antagonist ondansetron, all tested ginger constituents
acted as non-competitive antagonists, suggesting that ginger and its pungent constituents exert
antiemetic effects by blocking 5-HT-induced emetic signal transmission in vagal afferent neurons [58].
Interestingly, zingerone is the least pungent component of Zingiber officinale and is absent in fresh
ginger. However, gingerols is converted to zingerone upon cooking or heating. As a consequence,
this process reduces the 5-HT3A blocking activity of ginger [57]. Although all data showed that
ginger-derived molecules act allosterically, in silico techniques showed that these compounds can
also bind to the orthosteric binding site causing competitive inhibition as well [110]. Ginger extracts
were also tested against other ion channels such as L-type Ca2+ , Na+ and K+ channels. While gingerol
caused a dose-dependent inhibition of L-type Ca2+ channels in longitudinal mycocytes of rats, both
6-gingerol and 6-shagaol inhibited the generation of action potential in the sensory neurons of rats by
inhibiting Na+ and K+ channels [80].
4.3. Capsaicin
Capsaicin, from chili pepper, is another pungent substance that has shown effectiveness in
reversing emesis in chemotherapy and operation-induced nausea and vomiting [111,112] and in
Cannabis hyperemesis syndrome [113,114]. Capsaicin is chemically-related to other vanilloid substances
such as gingerols and shogaols. Capsaicin was also found to inhibit 5-HT3 receptor expressed in
Xenopus laevis oocytes [45]. When co-applied with 5-HT (5 µM), capsaicin (100 µM) significantly
decreased 5-HT-induced currents up to 52% compared to 83% for 8-gingerol, 62% for 6-gingerol, 42%
for 6-shogaol, and 65% for polygodial, the hot substance of dorrigo, mountain pepper or black pepper.
The concentration-inhibition curves showed that 8-gingerol, 6-gingerol, capsaicin and polygodial
blocked 5HT-induced inward currents in a concentration-dependent manner with IC50 values of 40 µM,
46 µM, 98 µM and 71 µM, respectively [45]. Other ion channels were also found to be modulated by
capsaicin. In fact, capsaicin was found to modulate both K+ and Ca2+ channels in Xenopus embryo
spinal neurons [45].
4.4. Eugenol and Vanilin
In addition to the previously mentioned compounds, other agents such as eugenol and vanillin
were also found to modulate the activity of 5-HT3 receptors. Both agents showed a non-competitive
antagonistic activity on 5-HT3 receptors expressed in Xenopus laevis oocytes, however, very high
concentrations of both compounds were needed to inhibit 5-HT response (IC50 1159 µM for eugenol
and IC50 4744 µM for vanillin) making them less effective compared to the other antagonists [45].
Eugenol could also inhibit the actions of different isoforms of T-type Ca2+ channels [83] and activate
the inhibitory receptor GABA [85,86].
4.5. Thujone
The monoterpene thujone is chemically related to menthol and found in plants such as wormwood,
thyme and sage [19]. Similar to menthol, thujone has been shown to non-competitively suppress
the function of 5-HT3 receptors. Using patch clamp technique, Alpha-thujone was found to cause a
significant inhibition of both homomeric and heteromeric 5-HT3 receptors expressed in HEK293 cells.
However, the effective concentration was typically in the high µM range [115]. Furthermore, other
ligand-gated ion channels were reported to be sensitive to thujone, including GABAA receptors and
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α7-nicotinic receptors. Thujone caused a non-competitive inhibition of both receptors expressed in
HEK 293 cells and Xenopus oocytes, respectively [94].
4.6. Cannabidiol
Previous studies showed that both 5-HT3 receptor antagonists and cannabinoids produce
antiemetic effects [32,59]. In fact, dronabinol and nabilone which are synthetically produced from
∆9 -tetrahydrocannabinol, the main psychoactive constituent of Cannabis sativa, were approved by
the United States FDA for use in CINV refractory to conventional antiemetic therapy [32,59,116].
The limitation of the therapeutic use of THC and its other chemical analogs is the potential development
of psychoactive effects through cannabinoid receptors (CB1) present in the central nervous system.
The compound cannabidiol is one of the most abundant cannabinoids of Cannabis plant with
reported antioxidant, anti-inflammatory, and antiemetic effects. Furthermore, this compound
lacks any psychoactive properties due to the low affinity for the cannabinoid receptors, CB1 and
CB2 [117–119]. Thus, pharmaceutical interest in this compound has increased significantly in recent
years [19,117,119,120]. The effect of cannabidiol on the function of 5-HT3A receptors expressed in
Xenopus laevis oocytes was investigated using two-electrode voltage-clamp techniques. Cannabidiol
was capable of reversing 5-HT-evoked currents in a concentration-dependent manner, with an
IC50 = 0.6 µM [121]. Although the potency of the 5-HT was not altered, its efficacy was significantly
decreased by cannabidiol, indicating that cannabidiol did not compete with the 5-HT binding site on
the receptor. In agreement with these findings, radioligand binding studies indicated that displacement
of [3 H]GR65630 by 5-HT was not significantly altered by cannabidiol, further suggesting that the
compound does not bind with 5-HT binding site. These findings indicate that cannabidiol acts as an
allosteric modulator of 5-HT3 receptor. Allosteric modulation by cannabidiol has also been reported
for several structurally different ion channels [117]. Cannabidiol caused a noncompetitive inhibition
of the α7-nicotinic receptors [91] in a manner similar to its action on the 5-HT3A receptors, while it
activated glycine receptors and TRPA1 channels [85,86].
4.7. Other Compounds
There are other natural compounds derived from plants which also target 5-HT3 receptors such
as the alkaloids cocaine and morphine (for review [60], both of which are potent competitive inhibitors
of 5-HT3 receptors (for review, [12]). Interestingly, quinine, the antimalarial drug, is a competitive
inhibitor of 5-HT3A receptors whereas it non-competitively inhibits 5-HT3AB receptors with a tenfold
less potency [13]. Local anesthetics such as lidocaine and bupivacaine, are also competitive and
allosteric antagonists at the 5-HT3A receptor [122].
In the current article, we have reviewed the effects of natural negative allosteric compounds on
5-HT3 receptors according to different preparations and a wide variety of techniques, ranging from
two-electrode voltage clamp to binding assays. Unlike 5-HT3 receptor selective antiemetic drugs
which bind at the 5-HT binding site, all the compounds reviewed in this article inhibit the 5-HT3
receptor by binding to a modulatory binding site distinct from the 5-HT recognition site. These
compounds did not compete with or displace the 5-HT3 antagonist, as evident in electrophysiological
and ligand binding studies. The therapeutic potential of allosteric ligands stems from their ability to
modulate receptor function while maintaining the native pattern of the receptor activation largely
intact [20,21]. By decreasing the efficacy of endogenous 5-HT3 receptor agonist, negative allosteric
modulators of 5-HT3 receptors can act as fine-tuning tools that may not affect physiological conditions,
but may be very active in pathophysiological states such as CINV, without causing complete receptor
inhibition [12]. This would lead to better safety profile compared to competitive antagonists. Since
allosteric sites exhibit greater structural diversity than orthosteric sites [18], they are more likely to
allow selective targeting by natural modulators.
In conclusion, the identification of allosteric binding sites for natural plant extracts and compounds
is expected to possess a promising outcome in developing novel anti-emetics lacking the typical side
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effects caused by setrons [106]. Considering the reported effects of allosteric modulatory compounds,
the development of novel antiemetic drugs based on naturally produced compounds may be possible.
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